Hirohiko Uchida
AstraZeneca (Japan) · 7 works · 283 citations · h-index 5
Top works
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
- [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
- Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA 3 trial
- Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
- Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples
- Accelerated hyperfractionation radiotherapy concurrently combined with chemotherapy for stageIII non-small cell lung cancer
- EGFR T790M変異陽性進行非小細胞肺癌の日本人患者におけるオシメルチニブ:AURA3試験